Who are Iontophoresis with acetylcholine delivery's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Succinylcholine Chloride, Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge, Chantix, Transdermal Nicoderm patch, Fentanyl/Atropine/Succinylcholine, Placebo Tablet and Nicotine Patch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iontophoresis-with-acetylcholine-delivery.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Iontophoresis with acetylcholine delivery — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iontophoresis with acetylcholine delivery (Iontophoresis with acetylcholine delivery) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic agent. Area: Neurology.

phase 2 Cholinergic agent Nicotinic acetylcholine receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Iontophoresis with acetylcholine delivery (Iontophoresis with acetylcholine delivery) — Assistance Publique - Hôpitaux de Paris. Acetylcholine delivery via iontophoresis stimulates nicotinic acetylcholine receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Iontophoresis with acetylcholine delivery TARGET	Iontophoresis with acetylcholine delivery	Assistance Publique - Hôpitaux de Paris	phase 2	Cholinergic agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Chantix	Varenicline Tartrate	Pfizer Inc.	marketed	Nicotinic receptor partial agonist	α4β2 neuronal nicotinic acetylcholine receptors
Transdermal Nicoderm patch	Transdermal Nicoderm patch	Ottawa Heart Institute Research Corporation	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Fentanyl/Atropine/Succinylcholine	Fentanyl/Atropine/Succinylcholine	King Saud University	marketed	Anesthetic combination (opioid + anticholinergic + neuromuscular blocker)	Mu-opioid receptor (fentanyl); muscarinic acetylcholine receptors (atropine); nicotinic acetylcholine receptors at neuromuscular junction (succinylcholine)
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-10-19 — Chantix · 11224598 · Method of Use · US
2035-10-19 — Chantix · 10456396 · Formulation · US
2035-10-19 — Chantix · 9597284 · Method of Use · US
2035-10-19 — Chantix · 9532944 · Method of Use · US
2035-10-19 — Chantix · 9504644 · Method of Use · US
2035-10-19 — Chantix · 11911380 · Method of Use · US
2035-10-19 — Chantix · 11903943 · Method of Use · US
2035-10-19 — Chantix · 11903941 · Method of Use · US
2035-10-19 — Chantix · 9504645 · Formulation · US
2035-10-19 — Chantix · 11903942 · Formulation · US

Sponsor landscape (Cholinergic agent class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Iontophoresis with acetylcholine delivery — Competitive Intelligence Brief. https://druglandscape.com/ci/iontophoresis-with-acetylcholine-delivery. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab